ReviewCancer cell international2022
Three-dimensional (3D) cell culture: a valuable step in advancing treatments for human hepatocellular carcinoma.
Review in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- A Microfibrous Extracellular Matrix Platform forACS pharmacology & translational science · 2026Article
- Cellular expansion of hepatocellular carcinoma organoids using decellularized liver scaffolds.Clinical transplantation and research · 2025Article
- Bridging dimensions: a comparative analysis of 2D and 3D in vitro models for hepatocellular carcinoma research.Archives of toxicology · 2025Article
- A Robust Marine Collagen Peptide-Agarose 3D Culture System for In Vitro Modeling of Hepatocellular Carcinoma and Anti-Cancer Therapeutic Development.Marine drugs · 2025Article
- Cyclodextrin-Based Metal-Organic Framework as an Application Platform for Bioactive Ruthenium(III) Complexes.Inorganic chemistry · 2025Article
- My cells, my model: immune-competent autologous organ-on-chip systems as a new paradigm in precision medicine.Frontiers in immunology · 2025Review
- Hedgehog components are overexpressed in a series of liver cancer cases.Scientific reports · 2024Article
- Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip.Nanotheranostics · 2024Review
- Esophageal adenocarcinoma models: a closer look.Frontiers in molecular biosciences · 2024Review
- Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates.Cancers · 2023Review
- Hyper-Branched Cationic Cyclodextrin Polymers for Improving Plasmid Transfection in 2D and 3D Spheroid Cells.Pharmaceutics · 2022Article
- Salvianolic acid B fromFrontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignant cancer and the third most frequent cause of tumour-related mortality worldwide. Currently, several surgical and medical therapeutic strategies are available for HCCs; however, the interaction between neoplastic cells and non-neoplastic stromal cells within the tumour microenvironment (TME) results in strong therapeutic resistance of HCCs to conventional treatment. Therefore, the development of novel treatments is urgently needed to improve the survival of patients with HCC. The first step in developing efficient chemotherapeutic drugs is the establishment of an appropriate system for studying complex tumour culture and microenvironment interactions. Three-dimensional (3D) culture model might be a crucial bridge between in vivo and in vitro due to its ability to mimic the naturally complicated in vivo TME compared to conventional two-dimensional (2D) cultures. In this review, we shed light on various established 3D culture models of HCC and their role in the investigation of tumour-TME interactions and HCC-related therapeutic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.